Blood-based biomarkers for malignant gliomas
نویسندگان
چکیده
منابع مشابه
Biomarkers classification and therapeutic decision-making for malignant gliomas.
OPINION STATEMENT Diffuse gliomas are the most common primary brain tumors, with glioblastoma (GBM) encompassing more than 50 % of all cases. Despite aggressive therapy, patients nearly always succumb to their disease and the survival for patients with GBM is approximately 1 year. During past years, numerous scientific contributions have reshaped the field of neuro-oncology and neuropathology. ...
متن کاملEvolvement of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas
Gliomas account for almost half of all diagnosed adult brain tumors (Siker et al., 2006). Glioblastoma multiforme (GBM), the most aggressive type of glioma, is also the most common primary malignant brain tumor. Even though tremendous effort has been made to treat high grade gliomas, the prognosis for patients with malignant gliomas remains poor. The dismal prognosis of patients with glioblasto...
متن کاملCellular immunotherapy for malignant gliomas.
INTRODUCTION Cancer immunotherapy has made much progress in recent years. Clinical trials evaluating a variety of immunotherapeutic approaches are underway in patients with malignant gliomas. Thanks to recent advancements in cell engineering technologies, infusion of ex vivo prepared immune cells have emerged as promising strategies of cancer immunotherapy. AREAS COVERED Herein, the authors r...
متن کاملGene Therapy for Malignant Gliomas
Retroviruses are enveloped RNA viruses that possess the ability to integrate into the host cell genome by transcribing DNA from their RNA template via viral reverse transcriptase. The transcribed viral DNA is then integrated into the host cell genome nonspecifically. There is relative specificity for tumors because, except for lentiviruses, retroviral DNA preferentially integrates into the geno...
متن کاملSURVIVAL IN PATIENTS WITH MALIGNANT GLIOMAS OF THE BRAIN
The present retrospective study was designed to analyze factors with prognostic values a) within, and b) significantly associated with, short-term (12months or less) and long-term (more than 24 months) survival times, i n 72 consecutive patients treated for malignant gliomas. Among 41 (57%) short-term surviving patients, the absence of both aphasia and motor deficit (as initial presenting ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neuro-Oncology
سال: 2013
ISSN: 0167-594X,1573-7373
DOI: 10.1007/s11060-013-1144-0